Author/Authors :
Tani، نويسنده , , Shigemasa and Nagao، نويسنده , , Ken and Anazawa، نويسنده , , Takeo and Kawamata، نويسنده , , Hirofumi and Furuya، نويسنده , , Shingo and Takahashi، نويسنده , , Hiroshi and Iida، نويسنده , , Kiyoshi and Matsumoto، نويسنده , , Michiaki and Washio، نويسنده , , Takehiko and Kumabe، نويسنده , , Narimichi and Hirayama، نويسنده , , Atsushi، نويسنده ,
Abstract :
Some investigations have looked into the ability of measurements of apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio to predict cardiovascular events. We hypothesized that a decrease in the apoB/apoA-1 ratio by statin therapy would act on suppression of coronary plaque progression. A 6-month prospective study was conducted of 64 patients with coronary artery disease treated with pravastatin. The plaque volume, assessed by volumetric intravascular ultrasonography, had decreased significantly by 12.6% (p <0.0001 vs baseline). Although a significant decrease of 6.4% and 14.6% was found in the serum level of apoB and the apoB/apoA-1 ratio (p = 0.0001 and p <0.0001, respectively, vs baseline), a significant increase of 14.0% of and 12.0% in the level of apoA-I and apoA-II (both p <0.0001 vs baseline). No significant changes were found in the level of apoC-II or apoE. A stepwise regression analysis revealed that the change in the apoB/apoA-1 ratio was an independent predictor of the change in coronary plaque volume (β coefficient 0.386; p = 0.0023). In conclusion, our results have indicated that the decrease in the apoB/apoA-I ratio is a simple predictor for coronary atherosclerotic regression: the lower the apoB/apoA-I ratio, the lower the risk of coronary atherosclerosis.
